Erectile dysfunction: Molecular biology, pathophysiology and pharmacological treatment

Minerva Urologica e Nefrologica

Volumn 57, Issue 2, 2005, Pages 85-90

  Morelli, A ^a   Vignozzi, L ^a   Filippi, S ^a   Mancina, R ^a   Maggi, M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Erectile dysfunction, diagnosis; Erectile dysfunction, physiopatology; Erectile dysfunction, therapy

Indexed keywords

ANDROGEN; CYCLIC GMP; NEUROTRANSMITTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; TESTOSTERONE; VARDENAFIL;

AGING; ANDROGEN DEFICIENCY; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SELECTIVITY; ENZYME REGULATION; ERECTILE DYSFUNCTION; HORMONE DEPENDENCE; HUMAN; ISCHEMIA; LIBIDO; MALE; MOLECULAR BIOLOGY; PATHOPHYSIOLOGY; PENIS ERECTION; REVIEW; RISK FACTOR; SMOOTH MUSCLE RELAXATION; SMOOTH MUSCLE TONE; TESTOSTERONE BLOOD LEVEL;

ADMINISTRATION, ORAL; CYCLIC GMP; HUMANS; IMPOTENCE; MALE; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITORS;

EID: 22144481665     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. NIH Consensus Development Panel on Impotence: Impotence. JAMA 1993;270:83-90.
2. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev 1995;75:191-236.
3. Andersson KE. Erectile physiological and pathophysiological pathways involved in erectile dysfunction. J Urol 2003;170:S6-S14.
4. Kim SW, Paick J, Park DW, Chae I, Oh B. Potential predictors of asymptomatic ischemic heart disease in patients with vasculogenic erectile dysfunction. Urology 2001;58:441-5.
5. Montorsi F, Salonia A, Montorsi P, Margonato A, Macchi A, Buzzetti F et al. May erectile dysfunction predict ischemic heart disease? J Urol 2002;167 Suppl 1:A591.
6. Saenz de Tejada I. Molecular mechanisms for the regulation of penile smooth muscle contractility. Int J Impot Res 2000;12 Suppl 4:S34-8.
7. Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M et al. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 2004;145:2253-63.
8. Mancina R, Filippi S, Marini M, Morelli A, Vignozzi L, Salonia A et al. Expression and functional activity of phosphodiesterase type 5 in human and rabbit vas deferens. Mol Hum Reprod 2005;11:107-15.
9. Vignozzi L, Corona G, Petrone L, Filippi S, Morelli A, Forti G et al. Testosterone and sexual activity. J Endocrinol Invest. In press 2005.
10. Zhang X-H, Morelli A, Luconi M, Vignozzi L, Filippi S, Marini M. Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum. Eur Urol 2005;47:409-16.
11. Rochira V, Birilli L, Madeo B, Balestrieri A, Granata AR, Carani C. Sex steroids and sexual desire mechanism. J Endocrinol Invest 2003;26:29-36.
12. Heim N, Hursch CJ. Castration for sex offenders: treatment or punishment? A review and critique of recent European literature. Archiv Sex Behav 1979;8:281-304.
13. Ellis WJ, Grayhack JT. Sexual function in aging males after orchidectomy and estrogen therapy. J Urol 1963;89:895-9.
14. Rousseau L, Dupont A, Labrie F, Couture M. Sexuality changes in prostate cancer patients receiving antihormonal therapy combining the antiandrogen flutamide with medical (LHRH agonist) or surgical castration. Archiv Sex Behav 1988;17:87-98.
15. Garban H, Vernet D, Freedman A, Rajfer J, Gonzalez-Cadavid N. Effect of aging on nitric oxide-mediated penile erection in rats. Am J Physiol 1995;268:H467-75.
16. Garban H, Marquez D, Cai L, Rajfer J, Gonzalez-Cadavid NF. Restoration of normal adult penile erectile response in aged rats by long-term treatment with androgens. Biol Reprod 1995;53:1365-72.
17. Vernet D, Cai L, Garban H, Babbitt ML, Murray FT, Rajfer J etal. Reduction of penile nitric oxide synthase in diabetic BB/WORdp (type I) and BBZ/WORdp (type II) rats with erectile dysfunction. Endocrinology 1995;136:5709-17.
18. Penson DF, Ng C, Rajfer J, Gonzalez-Cadavid NF. Adrenal control of erectile function and nitric oxide synthase in the rat penis. Endocrinology 1997;138:3925-32.
19. Penson DF, Ng C, Cai L, Rajfer J, Gonzalez-Cadavid NF. Androgen and pituitary control of penile nitric oxide synthase and erectile function in the rat. Biol Reprod 1996;55:567-74.
20. Mills TM, Wiedmeier VT, Stopper VS. Androgen maintenance of erectile function in the rat penis. Biol Reprod 1992;46:342-8.
21. Chamness SL, Ricker DD, Crone JK, Dembeck CL, Maguire MP, Burnett AL et al. The effect of androgen on nitric oxide synthase in the male reproductive tract of the rat. Fertil Steril 1995;63:1101-7.
22. Lugg JA, Rajfer J, Gonzalez-Cadavid NF. Dihydrotestosterone is the active androgen in the maintenance of nitric oxide-mediated penile erection in the rat. Endocrinology 1995;136:1495-501.
23. Lugg J, Ng C, Rajfer J, Gonzalez-Cadavid N. Cavernosal nerve stimulation in the rat reverses castration-induced decrease in penile NOS activity. Am J Physiol 1996;271: E354-61.
24. Park KH, Kim SW, Kim KD, Paick JS. Effects of androgens on the expression of nitric oxide synthase mRNAs in rat corpus cavernosum. BJU Int 1999;83:327-33.
25. Traish AM, Park K, Dhir V, Kim NN, Moreland RB, Goldstein I. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology 1999;140:1861-8.
26. Traish AM, Munarriz R, O'Connell L, Choi S, Kim SW, Kim NN et al. Effects of medical or surgical castration on erectile function in an animal model. J Androl 2003;24:381-7.
27. Takahashi Y, Hirata Y, Yokoyama S, Ishii N, Nunes L, Lue TF et al. Loss of penile erectile response to intracavernous injection of acetylcholine in castrated dog. Tohoku J Exp Med 1991;163:85-91.
28. Palese MA, Crone JK, Burnett AL. A castrated mouse model of erectile dysfunction. J Androl 2003;24:699-703.
29. Shen ZJ, Zhou XL, Lu YL, Chen ZD. Effect of androgen deprivation on penile ultrastructure. Asian J Androl 2003;5:33-6.
30. Shabsigh R, Raymond JF, Olsson CA, O'Toole K, Buttyan R. Androgen induction of DNA synthesis in the rat penis. Urology 1998;52:723-8.
31. Zhang XH, Hu LQ, Zheng XM, Li SW. Apoptosis in rat erectile tissue induced by castration. Asian J Androl 1999;1:181-5.
32. Kwan M, Greenleaf WJ, Mann J, Crapo L, Davidson JM. The nature of androgen action on male sexuality: a combined laboratory-self-report study on hypogonadal men. J Clin Endocrinol Metab 1983;57:557-62.
33. Burnett AL. The impact of sildenafil on molecular science and sexual health. Eur Urol 2004;46:9-14.
34. Gresser U, Gleiter CH. Erectile Dysfunction: Comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil-review of the literature. Eur J Med Res 2002;7:435-46.
35. Corbin JD, Francis SH. Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem 1999;274:13729-32.
36. Loughney K, Hill TR, Florio VA, Uher L, Rosman GJ, Wolda SL et al. Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3′,5′-cyclic nucleotide phosphodiesterase. Gene 1998;216:139-47.
37. Stacey P, Rulten S, Dapling A, Phillips SC. Molecular cloning and expression of human cGMP-binding cGMP-specific phosphodiesterase (PDE5). Biochem Biophys Res Commun 1998;247:249-54.
38. Yanaka N, Kotera J, Ohtsuka A, Akatsuka H, Imai Y, Michibata H et al. Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene. Eur J Biochem 1998;255:391-9.
39. Lin CS, Lin G, Lue TF. Isolation of two isoforms of phosphodiesterase 5 from rat penis. Int J Impot Res 2003;15:129-36.
40. Kuthe A, Magert H, Uckert S, Forssmann WG, Stief CG, Jonas U. Gene expression of the phosphodiesterases 3A and 5A in human corpus cavernosum penis. Eur Urol 2000;38:108-14.
41. Kotera J, Fujishige K, Imai Y, Kawai E, Michibata H, Akatsuka H et al. Genomic origin and transcriptional regulation of two variants of cGMP-binding cGMP-specific phosphodiesterases. Eur J Biochem 1999;262:866-72.
42. Shabsigh R. Hypogonadism and erectile dysfunction: the role for testosterone therapy. Int J Impot Res 2003;4:S9-13.
43. Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) 2003;58:632-8.
44. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004;172:658-63.
45. Corona G, Mannucci E, Mansani R, Petrone L, Bartolini M, Giommi R et al. Aging and pathogenesis of erectile dysfunction. Int J Impot Res 2004;16:395-402.
46. Corona G, Mannucci E, Mansani R, Petrone L, Bartolini M, Giommi R et al. Organic, relational and psychological factors in erectile dysfunction in men with diabetes mellitus. Eur Urol 2004;46:222-8.